Acadian Asset Management LLC Buys Shares of 1,272 LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Acadian Asset Management LLC purchased a new position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,272 shares of the medical instruments supplier’s stock, valued at approximately $104,000.

Several other institutional investors have also made changes to their positions in LMAT. PNC Financial Services Group Inc. lifted its position in LeMaitre Vascular by 4.9% in the 4th quarter. PNC Financial Services Group Inc. now owns 11,858 shares of the medical instruments supplier’s stock worth $673,000 after buying an additional 555 shares in the last quarter. Campbell & CO Investment Adviser LLC raised its holdings in shares of LeMaitre Vascular by 102.7% during the fourth quarter. Campbell & CO Investment Adviser LLC now owns 10,802 shares of the medical instruments supplier’s stock worth $613,000 after acquiring an additional 5,473 shares in the last quarter. Annex Advisory Services LLC boosted its position in LeMaitre Vascular by 105.4% during the fourth quarter. Annex Advisory Services LLC now owns 24,834 shares of the medical instruments supplier’s stock valued at $1,410,000 after purchasing an additional 12,745 shares during the last quarter. Personal CFO Solutions LLC grew its stake in LeMaitre Vascular by 6.4% in the fourth quarter. Personal CFO Solutions LLC now owns 5,574 shares of the medical instruments supplier’s stock valued at $316,000 after purchasing an additional 336 shares in the last quarter. Finally, Ranger Investment Management L.P. raised its stake in shares of LeMaitre Vascular by 1.5% during the 4th quarter. Ranger Investment Management L.P. now owns 912,503 shares of the medical instruments supplier’s stock worth $51,794,000 after purchasing an additional 13,681 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently commented on LMAT shares. Lake Street Capital assumed coverage on LeMaitre Vascular in a research note on Friday, August 2nd. They issued a “buy” rating and a $105.00 price target for the company. Barrington Research restated an “outperform” rating and set a $92.00 price target on shares of LeMaitre Vascular in a report on Friday. Roth Mkm reiterated a “buy” rating and issued a $100.00 price objective on shares of LeMaitre Vascular in a report on Friday, May 31st. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Finally, JMP Securities upped their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 20th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $94.40.

Insider Buying and Selling at LeMaitre Vascular

In other news, Director David B. Roberts sold 3,063 shares of the business’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total transaction of $251,380.41. Following the transaction, the director now owns 14,114 shares in the company, valued at approximately $1,158,335.98. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, Director David B. Roberts sold 3,063 shares of LeMaitre Vascular stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total transaction of $251,380.41. Following the sale, the director now owns 14,114 shares of the company’s stock, valued at approximately $1,158,335.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO George W. Lemaitre sold 27,030 shares of the company’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $86.27, for a total value of $2,331,878.10. Following the completion of the transaction, the chief executive officer now owns 1,958,328 shares of the company’s stock, valued at $168,944,956.56. The disclosure for this sale can be found here. Insiders sold a total of 43,251 shares of company stock valued at $3,714,994 in the last ninety days. Company insiders own 10.79% of the company’s stock.

LeMaitre Vascular Price Performance

LeMaitre Vascular stock opened at $89.96 on Friday. The firm has a market cap of $2.02 billion, a price-to-earnings ratio of 59.58, a P/E/G ratio of 2.28 and a beta of 0.88. The firm has a fifty day moving average price of $86.84 and a two-hundred day moving average price of $78.07. LeMaitre Vascular, Inc. has a fifty-two week low of $44.27 and a fifty-two week high of $92.90.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. The firm had revenue of $55.85 million during the quarter, compared to the consensus estimate of $54.98 million. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.37 EPS. As a group, sell-side analysts expect that LeMaitre Vascular, Inc. will post 1.85 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, August 29th. Investors of record on Thursday, August 15th were paid a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.71%. The ex-dividend date of this dividend was Thursday, August 15th. LeMaitre Vascular’s payout ratio is currently 42.38%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.